CRDF

Cardiff Oncology, Inc. (CRDF) - Q3 2024 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2024. Cardiff Oncology, Inc. is a clinical-stage biotechnology company developing novel cancer therapies based on Polo-like Kinase 1 (PLK1) inhibition. The company's lead asset is onvansertib, an oral PLK1 inhibitor currently in clinical trials for RAS-mutated metastatic colorectal cancer (mCRC), metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple-negative breast cancer (TNBC).

Key Financial Metrics

Note: Revenue consists entirely of royalty income from legacy intellectual property licenses unrelated to onvansertib.

Material Changes vs. Prior Period

• Revenue Growth: Royalty revenues increased 17% year-over-year for the quarter and 60% year-over-year for the nine-month period, driven by licensee sales activity.
• Expense Increases: Research and Development (R&D) expenses rose by $1.6 million for the quarter and $2.0 million for the nine-month period compared to 2023. This increase is primarily due to costs associated with clinical programs for onvansertib and increased headcount in R&D and clinical operations.
• SG&A Expenses: Selling, General, and Administrative expenses increased slightly for the quarter ($0.2 million) due to litigation settlement costs and stock-based compensation, but decreased for the nine-month period ($0.8 million) due to reduced severance costs compared to the prior year.
• Interest Income: Net interest income decreased to $0.7 million for the quarter (from $1.1 million) and $2.5 million for the nine-month period (from $3.1 million), reflecting fluctuations in cash balances and interest rates.

Outlook, Risks, and Unusual Items

• Clinical Milestones: The company anticipates releasing initial data from the CRDF-004 Phase 2 trial (first-line RAS-mutated mCRC) in the fourth quarter of 2024. Contingent on these results, the company plans to initiate a Phase 3 registrational trial (CRDF-005).
• Liquidity: Management believes current cash and short-term investments ($57.7 million) are sufficient to fund operations into the first quarter of 2026. However, the company expects to continue incurring losses and will require additional capital in the future.
• Capital Raising: During the quarter, the company raised $7.4 million net from the sale of common stock. In a subsequent event (Oct-Nov 2024), an additional $7.0 million gross was raised.
• Legal Settlement: The company settled a putative class action lawsuit regarding stockholder voting matters by agreeing to pay $400,000 in attorneys' fees, recorded in SG&A expenses for the quarter.
• Risks: Significant risks include the uncertainty of clinical trial outcomes, the need for additional financing which may cause dilution, and the competitive landscape of oncology therapeutics.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $57.7 million cash balance against projected burn rates to confirm the "into Q1 2026" liquidity guidance.
• CRDF-004 Trial Data: Monitor the release of initial data from the CRDF-004 Phase 2 trial in Q4 2024, as this is the primary catalyst for potential Phase 3 advancement.
• Dilution Impact: Review the impact of recent and future equity sales (Sales Agreement with Jefferies LLC) on share count and per-share value.
• R&D Spend Efficiency: Assess whether the increased R&D spend ($27.1 million YTD) correlates with tangible progress in patient enrollment and data readouts.
• Revenue Sustainability: Confirm the source and sustainability of royalty revenues, noting they are unrelated to the company's primary drug candidate, onvansertib.